3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for Study of Liver Diseases Annual Meeting 2012
11/12/2012 10:15:53 AM
More...
|
Efficacy and Safety Data From Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients With Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for Study of Liver Diseases
11/12/2012 10:09:53 AM
More...
|
American Association for Study of Liver Diseases Curriculum & Training (ACT) Launches With New Interactive HCV Education
11/12/2012 10:03:59 AM
More...
|
Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at American Association for Study of Liver Diseases 2012
11/12/2012 9:48:40 AM
More...
|
Synageva BioPharma (GEVA) Announces Six-Month Data From Extension Study of SBC-102 (sebelipase alfa) in Late Onset LAL Deficiency at the American Association for Study of Liver Diseases Annual Meeting
11/12/2012 9:26:29 AM
More...
|
Achillion Pharmaceuticals, Inc. (ACHN) Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for Study of Liver Diseases
11/12/2012 9:21:56 AM
More...
|
Interim Phase II Data of Merck & Co., Inc. (MRK)'s Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for Study of Liver Diseases Annual Meeting
11/12/2012 9:21:24 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Reports Clinical Data for HCV Drug Candidates - IDX719 and IDX184 - at the American Association for Study of Liver Diseases Annual Meeting
11/12/2012 8:00:57 AM
More...
|
Intercept Pharmaceuticals to Present Phase 2a Portal Hypertension Data at American Association for Study of Liver Diseases's Liver Meeting
11/9/2012 10:15:55 AM
More...
|
SCYNEXIS, Inc. to Report Phase 2a Study of SCY-635 for Treatment of HCV at American Association for Study of Liver Diseases
11/5/2012 9:17:07 AM
More...
|
|